Reported Q: Q2 2024 Rev YoY: +64.6% EPS YoY: +116.7% Move: -1.30%
WuXi XDC Cayman Inc
2268.HK
HKD64.45 -1.30%
Exchange HKSE Sector Healthcare Industry Medical Diagnostics Research
Q2 2024
Published: Jun 30, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 2268.HK

Reported

Report Date

Jun 30, 2024

Quarter Q2 2024

Revenue

832.60M

YoY: +64.6%

EPS

0.19

YoY: +116.7%

Market Move

-1.30%

Previous quarter: Q1 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $832.60M up 64.6% year-over-year
  • EPS of $0.19 increased by 116.7% from previous year
  • Gross margin of 32.1%
  • Net income of 244.11M
  • ""No earnings call transcript was provided in the input set."" - N/A
2268.HK
Company 2268.HK

Executive Summary

WuXi XDC Cayman Inc reported a strong QQ2 2024 with notable top-line growth and an expansion of profitability metrics, underpinned by a favorable mix of services and scale advantages in its CRO/CMO business. Revenue reached 832.60 million CNY, up 64.6% year-over-year, while gross profit rose 141.1% to 267.67 million CNY and gross margin improved to 32.15%. Operating income was 192.56 million CNY (operating margin 23.13%), supported by 88.30 million CNY of other income and expenses that buffered pretax profitability to 280.86 million CNY and led to net income of 244.11 million CNY (net margin 29.32%). Earnings per share stood at 0.19 CNY, up 116.7% year-over-year. Cash flow dynamics show negative operating cash flow of 112.33 million CNY, driven largely by non-cash and working capital effects, and capital expenditure of 260.92 million CNY, resulting in negative free cash flow of 373.25 million CNY for the quarter. The balance sheet remains liquidity-rich with substantial cash balances and a low debt burden, yielding a net debt position of approximately -3.41 billion CNY and a current ratio of 4.13x. Management commentary on QQ2 2024 and the broader market context was not provided in the supplied transcript, limiting direct quotes. Nevertheless, the quarterly performance signals a resilient growth trajectory in a structurally favorable ADC/CDMO market, though near-term cash flow headwinds from capex investments warrant close monitoring.Overall, the company demonstrates strong profitability, solid balance sheet strength, and favorable industry-driven growth, but investors should watch for capex-driven cash burn, order intake visibility, and competitive dynamics in the CRO/CMO space.

Key Performance Indicators

Revenue
Increasing
832.60M
QoQ: 0.00% | YoY: 64.59%
Gross Profit
Increasing
267.67M
32.15% margin
QoQ: 0.00% | YoY: 141.09%
Operating Income
Increasing
192.56M
QoQ: 0.00% | YoY: 89.25%
Net Income
Increasing
244.11M
QoQ: 0.00% | YoY: 152.86%
EPS
Increasing
0.19
QoQ: 0.00% | YoY: 116.65%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 1,350.43 0.28 +224.4% View
Q1 2025 1,350.43 0.28 +138.9% View
Q2 2024 832.60 0.19 +64.6% View
Q1 2024 832.60 0.19 +70.8% View